# Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)

> **NCT00862342** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 78 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab (Avastin)

## Key facts

- **NCT ID:** NCT00862342
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-12
- **Final completion:** 2012-06
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2012-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862342, "Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00862342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*